Keros Therapeutics (NASDAQ:KROS) Upgraded at Zacks Research

Keros Therapeutics (NASDAQ:KROS) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Thursday,Zacks.com reports.

KROS has been the topic of several other research reports. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Leerink Partners lowered their target price on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research note on Tuesday, August 4th. Wells Fargo & Company cut their price target on Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a report on Tuesday, August 4th. Wall Street Zen raised Keros Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, August 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Four investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $20.50.

Keros Therapeutics Trading Down 1.8%

Keros Therapeutics stock opened at $11.03 on Thursday. The stock has a 50-day moving average price of $10.78 and a 200 day moving average price of $11.61. Keros Therapeutics has a 52 week low of $9.69 and a 52 week high of $22.55. The stock has a market cap of $218.72 million, a PE ratio of -2.98 and a beta of 0.99.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. On average, equities analysts predict that Keros Therapeutics will post -5.27 EPS for the current year.

Insider Activity at Keros Therapeutics

In related news, Director Alpna Seth sold 2,625 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.72, for a total value of $28,140.00. Following the completion of the sale, the director directly owned 9,767 shares in the company, valued at approximately $104,702.24. The trade was a 21.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nima Farzan sold 2,625 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the sale, the director owned 9,767 shares of the company’s stock, valued at approximately $104,799.91. The trade was a 21.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,768 shares of company stock valued at $144,979 over the last three months. Insiders own 12.60% of the company’s stock.

Institutional Trading of Keros Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC acquired a new position in Keros Therapeutics in the first quarter valued at $226,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Keros Therapeutics by 15.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock valued at $227,000 after acquiring an additional 2,982 shares during the period. Goldman Sachs Group Inc. increased its stake in Keros Therapeutics by 38.3% during the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock worth $7,547,000 after acquiring an additional 205,022 shares during the last quarter. Creative Planning increased its stake in Keros Therapeutics by 40.2% during the second quarter. Creative Planning now owns 24,226 shares of the company’s stock worth $323,000 after acquiring an additional 6,948 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of Keros Therapeutics by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 51,815 shares of the company’s stock worth $692,000 after purchasing an additional 7,146 shares during the period. 71.56% of the stock is currently owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.